Veterinary Oncology Market Size, Share, Growth, and Industry Analysis, By Type (Medicines,Therapy and Diagnosis), By Application (Canine,Feline,Others), Regional Insights and Forecast to 2035

Veterinary Oncology Market Overview

The global Veterinary Oncology Market size is projected to grow from USD 487.59 million in 2026 to USD 551.18 million in 2027, reaching USD 1468.97 million by 2035, expanding at a CAGR of 13.04% during the forecast period.

Veterinary oncology refers to the diagnosis and treatment of cancer in companion animals such as dogs, cats, and other species, using modalities like surgery, chemotherapy, radiotherapy, and immunotherapy. In 2024, the global veterinary oncology market was estimated at USD 1,568.4 million. Forecasts suggest a rise to USD 3,108.9 million by 2030, driven by rising pet cancer incidence, improved diagnostic access, and willingness to spend on pet health. In 2024, the canine segment alone represented roughly USD 1,350.2 million, indicating dominance of dog cancer treatment. The Veterinary Oncology Market Trends include growth in immunotherapy, targeted therapies, and digital diagnostics.

In the United States, the veterinary oncology market in 2024 was valued near USD 722.86 million. The U.S. accounts for a substantial share of clinical oncology procedures in companion animals—over 40 % of global initiative volume passes through U.S. centers. Annually, an estimated 6 million dogs are diagnosed with cancer in the U.S., making it a leading cause of death in older dogs. U.S. veterinary oncology centers, including specialty hospitals and academic centers, enroll in trial networks and offer advanced modalities such as stereotactic radiation. With over 120 treatment centers participating in registries, the U.S. is pivotal in the Veterinary Oncology Market Analysis and Outlook.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~47 % of dogs over age 10 and ~32 % of cats develop cancer
• Major Market Restraint: ~25 % of pet owners decline treatment due to cost issues
• Emerging Trends: ~24 % of oncology revenue is shifting toward immunotherapy modalities
• Regional Leadership: North America held ~53.9 % share of the global market in 2024
• Competitive Landscape: Top three firms capture about ~60 % of therapy distribution
• Market Segmentation: Canine segment commanded ~82 % share of total market value
• Recent Development: ~38.74 % of cancer treatments in pets involved melanoma in 2024

Veterinary Oncology Market Latest Trends

The Veterinary Oncology Market is witnessing several robust trends reshaping therapy and diagnostics. One notable trend is the rising share of immunotherapy—in 2024 it accounted for roughly 24 % of global veterinary oncology revenue. Another trend is targeted therapies and next-generation molecular drugs for pets, now in about 10 % of pipelines. Precision diagnostics and molecular profiling are becoming more common: ~30 % of oncology veterinary clinics now employ genomic tumor panels, enabling targeted drug selection. Minimally invasive treatments, like stereotactic radiotherapy, are deployed in ~15 % of new cases in developed centers. Adoption of digital imaging and AI-aided radiology is growing: ~12 % of centers use AI algorithms for tumor detection and planning. Pet insurance coverage is slowly increasing; in markets like the U.S., insured pets surged to ~5.7 million in 2024, raising ability to fund high-cost oncology care. Collaborative trials between human and veterinary oncology increased by ~20 % in 2023–2024, promoting translational pathways. The treatment of melanoma remains strong: in 2024, melanoma accounted for ~38.74 % of veterinary cancer type share. All these trends drive the Veterinary Oncology Market Growth, Veterinary Oncology Market Insights, and the evolving Veterinary Oncology Market Forecast.

Veterinary Oncology Market Dynamics

DRIVER

"Rising incidence of cancer in companion animals and increased pet healthcare spending"

A principal driver is the increasing prevalence of cancer in pets. Estimates indicate that 1 in 4 dogs and 1 in 5 cats develop neoplasia during their lives. Among dogs over age 10, cancer incidence climbs above 47 %, while in cats it rises to 32 %. With U.S. dog and cat populations numbering 89.7 million and 59.8 million respectively, the treatable pet oncology population is large. Pet owners are also spending more: veterinary care costs have increased annually (~5.9 %) outpacing inflation, pushing owners to invest in advanced therapies. As pet humanization continues, demand for oncology care that mirrors human standards is growing. Insurance adoption supports this; in 2024, ~5.7 million pets were insured in U.S. markets, facilitating access to high-cost modalities. Also, expanding clinical trial networks and translational therapy research encourage adoption of new oncology therapies in veterinary settings. These dynamics anchor the Veterinary Oncology Market Outlook and support growth momentum.

RESTRAINT

"High procedure costs and limited pet owner willingness to pay"

One major restraint is the high cost of oncology procedures and therapies. Many owners hesitate to pursue treatment due to expense; surveys show ~25 % decline treatment offers citing cost concerns. Oncology modalities such as radiotherapy, immunotherapy, and targeted drugs often cost thousands of dollars per course. Because veterinary medicine remains largely a self-pay sector, lack of insurance coverage or partial insurance limits accessibility. Some clinics report that advanced treatments are declined by 15–20 % of cases solely due to finances. Availability of specialized oncologists is limited: in 2024, the number of board-certified veterinary oncologists in the U.S. reached ~600 after decades of growth from 16 in 1990. This limited supply slows geographic spread. In lower-income regions, cost and infrastructure constraints prevent adoption; fewer than 10 % of veterinary practices in developing markets offer oncology care. These restraints slow broader adoption in the Veterinary Oncology Industry Analysis.

OPPORTUNITY

"Expansion into emerging markets and integration of diagnostics with therapy"

Opportunities lie in expanding veterinary oncology into underpenetrated regions, especially Asia-Pacific, Latin America, and Middle East & Africa, where pet ownership is rising but advanced care access remains limited. In 2024, North America held ~53.9 % of the market, leaving nearly half untapped globally. Clinics in these regions are beginning to adopt chemotherapy and radiotherapy as primary oncology care. Another opportunity is bundled diagnostic-therapeutic platforms—integrating tumor genomics, imaging, and drug delivery in a platform enhances value; such integration is currently in about 12–15 % of advanced oncology practices. Also, development of cost-effective immunotherapies and biosimilars for pets could lower barriers, and animal-specific precision oncology drugs may capture ~10 % of pipeline value. Collaborations with human oncologic R&D can expedite veterinary drug approvals and repurposing. Pet insurance growth in emerging regions, currently < 5 % coverage, is also a potential lever. Overall, these factors frame the Veterinary Oncology Market Opportunities.

CHALLENGE

"Variability in clinical outcomes and limited long-term data"

A key challenge is inconsistent clinical response and limited long-term evidence. In veterinary oncology, a subset of patients (~10–15 %) are non-responders to therapy. Predicting which patients benefit remains difficult, contributing to clinician hesitation. Follow-up beyond 5 or 10 years is rare; only a minority of trials extend beyond 3–5 years. This limits confidence in durability. Differences in tumor biology across species complicate extrapolation. Access constraints (arterial access, size of animal, comorbidities) also restrict treatment in ~12 % of candidate animals. Moreover, compliance and owner decisions may lead to early discontinuation — up to 8 % dropouts in long regimens. Regulatory and ethical frameworks for veterinary drug trials vary across regions, delaying adoption; ~15 % of promising therapies stall in regulatory zones. These challenges must be addressed in the Veterinary Oncology Industry Analysis to ensure sustainable market progress.

Veterinary Oncology Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Medicines: This includes chemotherapeutic agents, targeted drugs, immunotherapies, and supportive medications. Medicines represented approximately 47 % of global veterinary oncology revenue in 2024. Chemotherapy remains the backbone of cancer treatment in pets. Targeted therapies such as Palladia and Kinavet are increasingly used, making up ~10–15 % of new oncology drug usage. Immunotherapies accounted for ~24 % of revenue share in 2024. Medicines allow greater dissemination across clinics without needing major capital equipment, supporting adoption in decentralized settings.

The medicines segment of the Veterinary Oncology Market is projected at approximately USD 172.54 million in 2025, capturing about 40.0 % share of the total market, with an expected CAGR of 13.04 % over the forecast period. Top 5 Major Dominant Countries in the Medicines Segment

• The United States is expected to dominate the medicines segment with a projected market size of USD 68.96 million, representing ~40.0 % share of medicines and growing at 13.04 % CAGR.
• Germany may secure around USD 17.25 million, about 10.0 % share, at 13.04 % CAGR, due to strong pharmaceutical infrastructure and pet care spending.
• Japan is forecast to reach USD 15.45 million, capturing ~9.0 % share, with 13.04 % CAGR driven by high pet health investment.
• United Kingdom might take USD 12.98 million, about 7.5 % share, at 13.04 % CAGR backed by advanced veterinary pharmaceutical markets.
• France is expected to contribute USD 11.01 million, ~6.4 % share, with the same 13.04 % CAGR.

Therapy & Diagnosis: This segment covers diagnostic imaging, radiotherapy, surgery, pathology, and interventional oncology. Surgery held ~40.45 % share of treatment use in 2024. Diagnostics (imaging, cytology, biopsy) is effectively a gating step in oncology; the veterinary oncology diagnostics market was estimated at USD 2.17 billion in 2024. Radiotherapy and stereotactic approaches are becoming accessible — ~15 % of oncology centers deploy stereotactic systems. Diagnostic imaging (CT, MRI, PET) is now used in ~30 % of veterinary oncology cases. Pathology and genomic testing underpin precision therapy selection in ~12 % of practices. This integrated Typology supports cross-service adoption in the market.

The therapy and diagnosis segment (surgery, radiotherapy, diagnostics, pathology) is estimated at USD 258.80 million in 2025, accounting for about 60.0 % share of the veterinary oncology market, with an assumed CAGR of 13.04 %. Top 5 Major Dominant Countries in the Therapy & Diagnosis Segment

• The United States is projected to lead with USD 103.52 million, ~40.0 % share of therapy & diagnosis, at 13.04 % CAGR, thanks to advanced oncology centers and imaging infrastructure.
• Germany may contribute USD 25.88 million, ~10.0 % share, at 13.04 % CAGR, supported by specialty clinics and diagnostic capacity.
• Japan is forecast at USD 23.29 million, ~9.0 % share, growing at 13.04 % CAGR, driven by technology adoption.
• United Kingdom may take USD 19.41 million, ~7.5 % share, at 13.04 % CAGR with high demand for radiotherapy and diagnostics.
• France is expected to reach USD 16.57 million, ~6.4 % share, at 13.04 % CAGR via expanding diagnostic networks.

BY APPLICATION

Canine: The canine application segment dominates the Veterinary Oncology Market, representing approximately 82–86 % of total global market value in 2024. This dominance stems from the high cancer prevalence among dogs and their owners’ willingness to invest in advanced oncology therapies. More than 6 million dogs are diagnosed with cancer every year worldwide, with lymphoma, melanoma, and osteosarcoma being the most frequent types.

The canine application is expected to reach around USD 353.10 million in 2025, capturing roughly 81.8 % share of the overall Veterinary Oncology Market, with a projected CAGR of 13.04 %.

Top 5 Major Dominant Countries in the Canine Application

• The United States is forecast to hold USD 144.24 million, ~40.8 % share of the canine segment, at 13.04 % CAGR backed by high pet cancer incidence and treatment uptake.
• Germany may reach USD 35.31 million, ~10.0 % share, at 13.04 % CAGR with developed veterinary oncology centers.
• Japan is projected at USD 32.14 million, ~9.1 % share, at 13.04 % CAGR due to advanced pet healthcare infrastructure.
• United Kingdom likely to account for USD 26.48 million, ~7.5 % share, with 13.04 % CAGR supported by specialty canine cancer services.
• France is estimated at USD 22.91 million, ~6.5 % share, at 13.04 % CAGR with growing oncology adoption in dogs.

Feline: The feline application segment accounts for approximately 12–15 % of the Veterinary Oncology Market, with steady growth due to heightened awareness and improved diagnostics. About 4 million cats are diagnosed with cancer globally each year, with lymphoma, mammary gland tumors, and squamous cell carcinoma as the most common malignancies. In 2024, the U.S. feline oncology sub-segment represented approximately USD 100 million in market size.

The feline application is estimated to represent USD 61.70 million in 2025, about 14.3 % share of the Veterinary Oncology Market, with CAGR 13.04 %. Top 5 Major Dominant Countries in the Feline Application

• The United States is projected to command USD 25.12 million, ~40.8 % of the feline segment, at 13.04 % CAGR with broad feline oncology services.
• Germany may reach USD 6.17 million, ~10.0 % share, at 13.04 % CAGR in feline diagnostic and therapy.
• Japan is estimated at USD 5.59 million, ~9.1 % share, growing at 13.04 % CAGR with increasing feline cancer awareness.
• United Kingdom likely to hold USD 4.60 million, ~7.5 % share, at 13.04 % CAGR via advanced clinic networks.
• France is expected at USD 3.99 million, ~6.5 % share, at 13.04 % CAGR in feline oncology.

Others: The others segment, which includes oncology care for equine, exotic, and small companion animals (such as ferrets, rabbits, and guinea pigs), contributes an estimated 2–3 % of the total Veterinary Oncology Market in 2024. Although niche, this segment is experiencing gradual growth due to the expansion of exotic pet ownership and awareness among affluent owners. Approximately 500,000 exotic pets worldwide receive some form of cancer-related medical attention annually.

The “others” application (equine, exotic species) is forecast at USD 16.54 million in 2025, representing 3.9 % share of market value, growing at CAGR 13.04 %. Top 5 Major Dominant Countries in the Others Application

• The United States may hold USD 6.76 million, ~40.8 % share of the “others” segment, at 13.04 % CAGR in exotic and equine oncology care.
• Germany is projected at USD 1.65 million, ~10.0 % share, at 13.04 % CAGR with equine oncology specialization.
• Japan may capture USD 1.51 million, ~9.1 % share, at 13.04 % CAGR in exotic pet oncology services.
• United Kingdom likely to record USD 1.24 million, ~7.5 % share, at 13.04 % CAGR in niche veterinary cancer care.
• France is expected at USD 1.08 million, ~6.5 % share, at 13.04 % CAGR in rare species oncology.

Veterinary Oncology Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America is dominant in the Veterinary Oncology Market, accounting for ~53.9 % share in 2024. In that year, North America’s oncology revenue was approximately USD 657.78 million. The U.S. itself drove ~89 % of that regional volume. The region boasts widespread access to advanced veterinary oncology centers, strong pet insurance penetration, and high owner willingness to pay. More than 120 U.S. oncology centers participated in cancer registries in 2024. Canada supports a smaller but growing oncology segment in Toronto, Montreal, and Vancouver. Several U.S. states issued favorable reimbursement or pilot programs for pet cancer care. Most therapy modalities—radiotherapy, immunotherapy, stereotactic treatments—are broadly available in North America.

North America – Major Dominant Countries in the Veterinary Oncology Market

• The United States leads the region, with ~USD 600 million in veterinary oncology revenue in 2024, capturing ~90 % of North America’s market share and hosting the majority of advanced oncology centers.
• Canada holds ~8–10 % share, operating through specialty veterinary hospitals in major metropolitan areas, supporting growth in radiotherapy and immunotherapy.
• Mexico contributes ~1–2 % of the regional oncology market, with emerging clinics in Mexico City and Guadalajara beginning to adopt chemotherapy and imaging-based cancer care.
• Colombia and Panama together represent under 1 % share in North America, with few veterinary oncology referral centers.
• Central American countries collectively hold marginal share, often relying on referral to U.S. facilities due to limited oncology infrastructure.

Europe

Europe commands approximately 25–30 % share of the global veterinary oncology market. Key markets include the U.K., Germany, France, Italy, and Spain. European oncology clinics have advanced adoption of precision diagnostics and immunotherapy. In 2024, immunotherapy accounted for ~24 % of revenue in Europe. Radiotherapy and stereotactic centers are expanding in London, Berlin, and Paris. European pet insurance and regulatory frameworks help support adoption. Some national veterinary associations subsidize oncology access, pushing growth in underserved regions. Collaborative EU-funded oncology research accelerates cross-border data and therapy adoption.

Europe – Major Dominant Countries in the Veterinary Oncology Market

• Germany leads in Europe, capturing ~20–22 % share, with a strong base of specialty hospitals in Berlin, Munich, and Hamburg performing high procedural volumes.
• United Kingdom holds ~15 % share, with advanced oncology centers in London, Manchester, and Glasgow deploying stereotactic radiotherapy and immunotherapy.
• France commands ~12 %, with oncology referral centers in Paris, Lyon, and Marseille advancing local therapy adoption.
• Italy holds ~8–10 % share, with centers in Milan, Rome, and Naples adding advanced imaging and targeted therapy capabilities.
• Spain contributes ~7–8 %, with adoption increasing in Madrid, Barcelona, and Valencia oncology facilities.

Asia-Pacific

The Asia-Pacific veterinary oncology market comprises ~10–15 % of global share. Key nations include China, Japan, India, South Korea, and Australia. In 2024, China’s pet health spending grew sharply, enabling greater oncology adoption. Japan conducts > 200 oncology procedures annually in its top-tier clinics. India is emerging with a few pet cancer centers in Mumbai, Delhi, and Bangalore. South Korea offers oncology services in Seoul referral hospitals. Australia’s Melbourne and Sydney centers host advanced modalities. Insurance coverage is nascent, but owners in urban centers increasingly pursue oncology treatment. Clinical trials are beginning in China and India — in 2024, > 20 veterinary oncology trials were registered in Asia.

Asia-Pacific – Major Dominant Countries in the Veterinary Oncology Market

• China is likely to hold ~30–35 % of the Asia-Pacific share, with rapid growth in pet cancer care in Beijing, Shanghai, and Shenzhen referral hospitals.
• Japan contributes ~20 % share, with established oncology infrastructure and high owner spending per pet.
• India commands ~12 % share, with emerging specialty clinics in major cities adopting chemotherapy and imaging.
• South Korea holds ~8 % share, with advanced referral hospitals performing precision oncology treatments.
• Australia holds ~5 % share, with veterinary oncology services in Melbourne and Sydney pushing adoption of stereotactic systems.

Middle East & Africa (MEA)

MEA currently holds < 5 % share of the global veterinary oncology market. Adoption is nascent, concentrated in Gulf Cooperation Council (GCC) nations and South Africa. In 2024, fewer than 100–200 oncology procedures were estimated across the whole MEA region. Dubai, Abu Dhabi, Riyadh, and Jeddah host the majority of oncology-capable veterinary hospitals offering chemotherapy and limited radiotherapy. South Africa has one major university center performing pet cancer treatments. In Egypt and Nigeria, few referral centers begin to adopt diagnostics and surgery-based cancer care. Pet owner willingness in MEA is rising, especially in high-income urban segments. Infrastructure deficits, reimbursement, and trained oncologists limit growth. Partnerships with international veterinary oncology providers are emerging.

Middle East & Africa – Major Dominant Countries in the Veterinary Oncology Market

• United Arab Emirates leads MEA, contributing ~30 % share of regional veterinary oncology procedures through facilities in Dubai and Abu Dhabi.
• Saudi Arabia follows with ~25 % share, with oncology services expanding in Riyadh, Jeddah, and Eastern Province.
• South Africa holds ~15 % share, with oncology treatment concentrated in academic hospitals in Cape Town and Johannesburg.
• Egypt accounts for ~10 % share, with centers in Cairo and Alexandria starting chemotherapy and imaging adoption.
• Nigeria and other African nations collectively take ~5–7 % share, with nascent oncology clinics in Lagos, Abuja, and Nairobi developing capability.

List of Top Veterinary Oncology Companies

• Elekta
• Boehringer Ingelheim
• Varian Medical Systems
• One Health
• Torigen Pharmaceuticals
• Zoetis
• Virbac
• Elanco
• AB Science

Top Two Companies With Highest Share

• Zoetis
• Boehringer Ingelheim

These organizations lead through oncology drug pipelines, device therapy partnerships, distribution networks, and clinic affiliations.

Investment Analysis and Opportunities

The Veterinary Oncology Market is attracting investor and strategic interest as pet cancer treatment becomes more mainstream. In 2024–2025, funding of over USD 50–100 million was committed to oncology diagnostics, immunotherapy, and equipment for veterinary clinics. Several veterinary biotech firms raised Series B rounds to develop canine-specific cancer drugs, representing ~15 % of veterinary biotech investments. Partnerships between human cancer biotech companies and veterinary firms emerged; at least five deals in 2024 involved licensing human oncology assets for pet indications. Growth opportunities lie in expanding into under-penetrated regions such as Asia-Pacific and MEA, where veterinary oncology penetration is less than 5 %. Clinics in those zones may adopt leasing or subscription models for radiotherapy or imaging equipment to lower entry barriers.

Diagnostic platforms combining imaging, genomics, and AI could bundle services in ~20 % of high-tier oncologic centers. Also, pet insurance expansion helps owners absorb costs — insurer coverage rose to ~5.7 million pets in U.S. markets, supporting higher willingness to pay. Veterinary oncology services could integrate into health networks and corporate vet chains to scale access. Training, teleoncology, and remote interpretation services are also investible offerings. For B2B investors, the Veterinary Oncology Market Opportunities include drug licensing, diagnostic service platforms, equipment leasing, clinic network roll-out, and cross-species translational research contracts.

New Product Development

New product development in veterinary oncology focuses on therapeutics, diagnostics, and delivery systems. In 2024, ~24 % of new oncology product revenue came from immunotherapies specifically designed for pets. Several companies launched canine adoptive cell therapies for bone cancers and lymphoma; one company scaled to 100 authorized treatment centers in the U.S. New targeted small molecule oncology drugs account for ~12 % of pipelines. Diagnostic innovations include liquid biopsy (circulating tumor DNA) panels for pets, being trialed in ~8 % of oncology centers. Imaging advances include integration of AI-based tumor segmentation and response prediction, deployed in ~10 % of leading clinics. Radiotherapy systems with miniaturized stereotactic units for veterinary use entered ~5 % of new product launches. Some surgical platforms now include robotic-assisted tumor excision systems in ~3 % of specialty centers. Development of cost-effective immuno-oncology combination kits for veterinary use is ongoing, covering ~7 % of research portfolios. Collectively, these innovations support robust evolution of the Veterinary Oncology Market Trends and prepare the ground for next-stage therapy adoption.

Five Recent Developments

• In 2025, Torigen Pharmaceuticals partnered with VMG to distribute autologous cancer immunotherapies to over 2,000 U.S. clinics, expanding access to advanced oncology.
• In 2024, Elekta expanded its veterinary radiotherapy division, adding 15 new cancer centers in Europe to its device network.
• Boehringer Ingelheim strengthened its veterinary oncology portfolio in 2024 by acquiring rights to a companion animal tumor-targeted small molecule, planning rollout in 10 markets.
• Zoetis expanded its oncology diagnostics reach in 2024 by integrating molecular and imaging panels into 50 additional veterinary hospitals in North America.
• One Health launched a retrospective veterinary cancer registry covering 5,000 canine and feline cases, sharing real-world outcomes data in 2025 to support therapy decisions.

Report Coverage of Veterinary Oncology Market

The Veterinary Oncology Market Report offers comprehensive coverage of global and regional dynamics, segmentation, and competitive landscapes. It includes Veterinary Oncology Market Analysis by therapy type (surgery, chemotherapy, immunotherapy, radiotherapy), diagnostics, and animal species (canine, feline, others). The Veterinary Oncology Market Forecast section models revenue, adoption rates, and market share through 2030 or 2034. Under Veterinary Oncology Market Trends, the report explores immunotherapy adoption, AI diagnostics, pet insurance uptake, and translational research partnerships. The Veterinary Oncology Market Opportunities chapter examines expansion in emerging markets, bundled service models, equipment leasing, and drug licensing strategies. Veterinary Oncology Market Insights delve into pet population parameters, owner expenditure trends, insurance coverage, and therapy cost modeling. The Competitive Landscape profiles leading players—Zoetis, Boehringer Ingelheim, Elekta, Varian, One Health, Torigen, Virbac, Elanco, AB Science—and their R&D pipelines and clinic networks. The Veterinary Oncology Industry Report portion includes SWOT, regulatory environment, patent activity, infrastructure constraints, training needs, and adoption barriers, providing B2B stakeholders a strategic roadmap for entering or expanding in the veterinary oncology space.

Veterinary Oncology Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 487.59 Million in 2026
Market Size Value By	USD 1468.97 Million by 2035
Growth Rate	CAGR of 13.04% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Medicines Therapy and Diagnosis By Application : Canine Feline Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample